S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: The truth about war with China (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
BREAKING: The truth about war with China (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: The truth about war with China (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
BREAKING: The truth about war with China (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: The truth about war with China (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
BREAKING: The truth about war with China (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
BREAKING: The truth about war with China (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
BREAKING: The truth about war with China (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
NASDAQ:ATRC

AtriCure (ATRC) Stock Forecast, Price & News

$43.80
-0.11 (-0.25%)
(As of 09/29/2023 ET)
Compare
Today's Range
$43.54
$44.64
50-Day Range
$41.12
$57.73
52-Week Range
$32.51
$59.61
Volume
403,778 shs
Average Volume
301,862 shs
Market Capitalization
$2.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.4% Upside
$65.00 Price Target
Short Interest
Bearish
2.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of AtriCure in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$195,077 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

387th out of 970 stocks

Surgical & Medical Instruments Industry

49th out of 99 stocks


ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Price History

ATRC Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
AtriCure: Q2 Earnings Snapshot
Q2 2023 AtriCure Inc Earnings Call
What Wall Street expects from AtriCure's earnings
AtriCure: Operating Leverage Is Required As A Cure
ATRC - AtriCure, Inc.
Needham Reaffirms Their Buy Rating on Atricure (ATRC)
AtriCure, Inc. (ATRC)
Q1 2023 AtriCure Inc Earnings Call
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
7/25/2023
Today
9/30/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,050
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$65.00
High Stock Price Forecast
$74.00
Low Stock Price Forecast
$56.00
Forecasted Upside/Downside
+48.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-46,470,000.00
Pretax Margin
-7.57%

Debt

Sales & Book Value

Annual Sales
$330.38 million
Book Value
$9.82 per share

Miscellaneous

Free Float
45,978,000
Market Cap
$2.08 billion
Optionable
Optionable
Beta
1.37

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Michael H. Carrel (Age 52)
    CEO, Pres & Director
    Comp: $1.62M
  • Ms. Angela L. Wirick CPAMs. Angela L. Wirick CPA (Age 45)
    Chief Financial Officer
    Comp: $668.62k
  • Mr. Douglas J. SeithMr. Douglas J. Seith (Age 57)
    Chief Operating Officer
    Comp: $989.17k
  • Mr. Justin J. NozneskyMr. Justin J. Noznesky (Age 45)
    Chief Marketing & Strategy Officer
    Comp: $644.73k
  • Ms. Deborah Yount (Age 57)
    Chief HR Officer
    Comp: $498.36k
  • Mr. Salvatore Privitera J.D.Mr. Salvatore Privitera J.D. (Age 56)
    Chief Technical Officer
  • Dr. Vinayak Doraiswamy Ph.D. (Age 51)
    Chief Scientific Officer
  • Mr. Karl S. Dahlquist C.C.E.P. (Age 53)
    CCEP, J.D., Chief Legal Officer
  • Valerie Storch-Willhaus
    VP of Corp. Marketing & Communications













ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2023?

5 Wall Street analysts have issued 1-year target prices for AtriCure's shares. Their ATRC share price forecasts range from $56.00 to $74.00. On average, they anticipate the company's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2023?

AtriCure's stock was trading at $44.38 at the beginning of the year. Since then, ATRC stock has decreased by 1.3% and is now trading at $43.80.
View the best growth stocks for 2023 here
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its earnings results on Tuesday, July, 25th. The medical device company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.15. The medical device company earned $100.92 million during the quarter, compared to analyst estimates of $97.55 million. AtriCure had a negative net margin of 7.67% and a negative trailing twelve-month return on equity of 7.11%. AtriCure's revenue for the quarter was up 19.4% on a year-over-year basis. During the same period last year, the company posted ($0.32) EPS.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of -$0.94--$0.92 for the period, compared to the consensus estimate of -$1.02. The company issued revenue guidance of $392.00 million-$395.00 million, compared to the consensus revenue estimate of $388.31 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $43.80.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.08 billion and generates $330.38 million in revenue each year. The medical device company earns $-46,470,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does AtriCure have?

The company employs 1,050 workers across the globe.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -